Tribo-Charging Behaviour of Inhalable Mannitol Blends with Salbutamol Sulphate.
dry powder inhaler (DPI)
inhalation
particle/material properties
powder blends
powder processing
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
09 Apr 2019
09 Apr 2019
Historique:
received:
17
12
2018
accepted:
19
03
2019
entrez:
11
4
2019
pubmed:
11
4
2019
medline:
23
4
2019
Statut:
epublish
Résumé
The performance of carrier-based dry powder inhaler (DPI) formulations can be critically impacted by interfacial interactions driven by tribo-electrification. Therefore, the aim of the present work was to understand how distinct API particle characteristics affect the charging behaviour of blends intended for DPI delivery. Salbutamol sulphate (SBS) particles engineered via spray-drying and jet milling were used as model APIs. D-mannitol was selected as a model carrier. The materials were characterized concerning their different particle properties and their charge was analysed alone and in blends before and after flow over a stainless-steel pipe. The spray-dried SBS (amorphous and spherical) charged positively and to a higher extent than jet milled SBS (crystalline and acicular) that charged negatively and to a lower extent. D-mannitol charged positively and to a higher extent than the APIs. All drug-excipient blends charged negatively and differences were found between the spray-dried and jet milled SBS blends at 2% and 5% drug loads. It was demonstrated how distinct solid-states, particle shape, size and morphology as well as different water contents of the different materials can affect tribo-charging. For their binary blends, the amount and nature of fines seem to govern inter-particle contacts critically impacting charge evolution.
Identifiants
pubmed: 30968221
doi: 10.1007/s11095-019-2612-9
pii: 10.1007/s11095-019-2612-9
pmc: PMC6456482
doi:
Substances chimiques
Drug Carriers
0
Excipients
0
Powders
0
Mannitol
3OWL53L36A
Albuterol
QF8SVZ843E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Subventions
Organisme : Österreichische Forschungsförderungsgesellschaft
ID : COMETprogram
Références
Soft Matter. 2017 Jan 4;13(2):394-401
pubmed: 27973634
Drug Dev Ind Pharm. 2007 Sep;33(9):967-74
pubmed: 17891583
Int J Pharm. 2015 Aug 1;491(1-2):231-42
pubmed: 26136200
Int J Pharm. 2015 Aug 1;491(1-2):58-68
pubmed: 26043824
Int J Pharm. 2018 Jan 30;536(1):326-335
pubmed: 29217472
Phys Rev E. 2017 Jan;95(1-1):012901
pubmed: 28208496
Int J Pharm. 2007 Feb 22;331(1):93-8
pubmed: 17052870
Int J Pharm. 2007 Apr 4;334(1-2):85-91
pubmed: 17113733
Phys Rev E Stat Nonlin Soft Matter Phys. 2009 May;79(5 Pt 1):051304
pubmed: 19518446
Int J Pharm. 2002 Jul 8;241(1):73-85
pubmed: 12086723
J Pharm Sci. 2000 Apr;89(4):457-68
pubmed: 10737907
Adv Drug Deliv Rev. 2012 Mar 15;64(3):233-56
pubmed: 21616107
Pharm Res. 2014 Jan;31(1):60-76
pubmed: 23918220
Sci Rep. 2014 Mar 18;4:4399
pubmed: 24637964
Sci Rep. 2018 Feb 6;8(1):2472
pubmed: 29410440
Ther Deliv. 2013 Aug;4(8):981-1002
pubmed: 23919475
Int J Pharm. 2016 Apr 30;503(1-2):262-76
pubmed: 26836710
ACS Omega. 2017 Apr 21;2(4):1576-1582
pubmed: 31457523
Int J Pharm. 2017 Aug 7;528(1-2):416-428
pubmed: 28619456
Pharm Res. 2014 Jul;31(7):1656-64
pubmed: 24464269
Phys Rev E. 2017 Jun;95(6-1):062903
pubmed: 28709334
Phys Rev Lett. 2009 Jan 16;102(2):028001
pubmed: 19257320
Eur J Pharm Sci. 2014 Dec 18;65:1-8
pubmed: 25193137
Drug Discov Today. 2014 May;19(5):618-26
pubmed: 24269834